Chimeric antigen receptor and natural killer cells expressing same
AssigneeGreen Cross Lab Cell Corporation
InventorsYu Kyeong HWANG, Sung Yoo CHO, Sung Yong WON, Ho Yong LIM, Jung Hyun HER, Mi Young JUNG, Hyun Ah KIM, Su Hyun GWON, Eun Sol LEE, Han Sol KIM
Life of this patent
Estimating the term…
Abstract
The present invention provides a chimeric antigen receptor and natural killer cells expressing the same, and particularly, a chimeric antigen receptor (CAR) which includes an intracellular signaling domain including the whole or a portion of an OX40 ligand (CD252), thereby having excellent effects of increasing anticancer activity of immune cells, and immune cells expressing the same.
Claims33
1-30. (canceled)
A chimeric antigen receptor, comprising:
- an intracellular signaling domain which includes the whole or a portion of OX40 ligand (CD252).
A chimeric antigen receptor, comprising intracellular signaling domains which comprise:
- a first intracellular signaling domain including the whole or a portion of any one selected from the group consisting of CD28 and 4-1BB;
- a second intracellular signaling domain including the whole or a portion of any one selected from the group consisting of OX40 ligand, OX40 and 4-1BB;
- and
- a third intracellular signaling domain including the whole or a portion of CD3-zeta,
- wherein the first, second and third intracellular signaling domains are arranged in order from a cell membrane toward an inside of the cell.
Dependencies are inferred from the claim text.